To determine whether activation of EGFR, PI3K/Akt, or MAPK/ERK signaling pathways is involved in icotinib-induced cell cycle arrest and/or apoptosis in NSCLC cells, we detected activation of EGFR, Akt, and ERK in HCC827 cells treated with 0.01, 0.1, and 1 μM icotinib for 24 h. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.